S&P Futures
6,005.50 +1.75 (+0.03%) Dow Futures
43,909.00 -1.00 (-0.00%) Nasdaq Futures
21,228.75 +4.00 (+0.02%) Russell 2000 Futures
2,395.40 -0.30 (-0.01%) Crude Oil
71.81 -0.55 (-0.76%) Gold
2,690.70 -15.10 (-0.56%)
IN8bio Inc (6JH.SG)
| Previous Close | 0.3160 |
| Open | 0.3060 |
| Bid | 0.3060 x N/A |
| Ask | 0.3160 x N/A |
| Day's Range | 0.3060 - 0.3160 |
| 52 Week Range | 0.2000 - 1.7500 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireIN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. Details for the ASH 2024 presentation are as follows: Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infus
- Zacks Small Cap Research
INAB: Restructuring Narrows Focus to AML
By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) announced a restructuring in a September 4th press release indicating that the company will focus on the INB-100 program for acute myeloid leukemia (AML). Due to the difficult financing environment and investor lack of interest in pursuing a glioblastoma multiforme (GBM) program, IN8bio has decided
